ezetimibe has been researched along with Vascular Calcification in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, L | 1 |
| Al Kindi, M; Al Rasadi, K; Al Waili, K; Aljenedil, S; Awan, Z; Bélanger, AM; Genest, J; Ruel, I; Sayegh, K; Senouci, S; Sivakumaran, L; Valenti, D | 1 |
2 other study(ies) available for ezetimibe and Vascular Calcification
| Article | Year |
|---|---|
A practical approach to the cholesterol guidelines and ASCVD prevention.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Autoimmune Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Reduction Behavior; Secondary Prevention; Vascular Calcification | 2020 |
Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Aorta; Aortic Diseases; Calcium; Cholesterol, LDL; Ezetimibe; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Receptors, LDL; Tomography, X-Ray Computed; Vascular Calcification | 2017 |